Seres Therapeutics, Inc. (MCRB) stock
MCRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$1.41+0.00 (0.00%)
Close on Nov 17, 2026Market cap $14.02MP/E –Yield –
Seres Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Seres Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$80.59M. For fiscal 2025 it was -$89.84M. The highest annual figure on record is -$5.96M in fiscal 2013.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$89.84M | – |
| FY2024 | Dec 31, 2024 | -$115.85M | – |
| FY2023 | Dec 31, 2023 | -$188.85M | – |
| FY2022 | Dec 31, 2022 | -$173.29M | – |
| FY2021 | Dec 31, 2021 | -$58.55M | – |
| FY2020 | Dec 31, 2020 | -$81.55M | – |
| FY2019 | Dec 31, 2019 | -$64.27M | – |
| FY2018 | Dec 31, 2018 | -$92.42M | – |
| FY2017 | Dec 31, 2017 | -$84.14M | – |
| FY2016 | Dec 31, 2016 | -$88.63M | – |
| FY2015 | Dec 31, 2015 | -$54.13M | – |
| FY2014 | Dec 31, 2014 | -$14.89M | – |
| FY2013 | Dec 31, 2013 | -$5.96M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$20.60M | – |
| Q1 FY2026 | Mar 31, 2026 | -$20.13M | – |
| Q4 FY2025 | Dec 31, 2025 | -$18.42M | – |
| Q3 FY2025 | Sep 30, 2025 | -$21.43M | – |
| Q2 FY2025 | Jun 30, 2025 | -$23.82M | – |
| Q1 FY2025 | Mar 31, 2025 | -$26.16M | – |
| Q4 FY2024 | Dec 31, 2024 | -$27.75M | – |
| Q3 FY2024 | Sep 30, 2024 | -$27.77M | – |
| Q2 FY2024 | Jun 30, 2024 | -$27.45M | -153.8% |
| Q1 FY2024 | Mar 31, 2024 | -$32.88M | – |
| Q4 FY2023 | Dec 31, 2023 | -$35.39M | – |
| Q3 FY2023 | Sep 30, 2023 | -$42.90M | – |
| Q2 FY2023 | Jun 30, 2023 | $51.05M | – |
| Q1 FY2023 | Mar 31, 2023 | -$69.17M | – |
| Q4 FY2022 | Dec 31, 2022 | -$104.00K | – |
| Q3 FY2022 | Sep 30, 2022 | -$57.36M | -182.1% |
| Q2 FY2022 | Jun 30, 2022 | -$61.64M | – |
| Q1 FY2022 | Mar 31, 2022 | -$54.18M | – |
| Q4 FY2021 | Dec 31, 2021 | -$47.88M | – |
| Q3 FY2021 | Sep 30, 2021 | $69.90M | – |
| Q2 FY2021 | Jun 30, 2021 | -$46.72M | – |
| Q1 FY2021 | Mar 31, 2021 | -$33.85M | – |
| Q4 FY2020 | Dec 31, 2020 | -$16.39M | – |
| Q3 FY2020 | Sep 30, 2020 | -$28.42M | – |
| Q2 FY2020 | Jun 30, 2020 | -$18.85M | – |
| Q1 FY2020 | Mar 31, 2020 | -$17.89M | – |
| Q4 FY2019 | Dec 31, 2019 | -$17.39M | – |
| Q3 FY2019 | Sep 30, 2019 | -$15.31M | – |
| Q2 FY2019 | Jun 30, 2019 | -$9.03M | – |
| Q1 FY2019 | Mar 31, 2019 | -$22.55M | – |
| Q4 FY2018 | Dec 31, 2018 | -$19.68M | – |
| Q3 FY2018 | Sep 30, 2018 | -$20.24M | – |
| Q2 FY2018 | Jun 30, 2018 | -$26.18M | – |
| Q1 FY2018 | Mar 31, 2018 | -$26.33M | – |
| Q4 FY2017 | Dec 31, 2017 | -$27.87M | – |
| Q3 FY2017 | Sep 30, 2017 | -$5.45M | – |
| Q2 FY2017 | Jun 30, 2017 | -$26.66M | – |
| Q1 FY2017 | Mar 31, 2017 | -$24.16M | – |
| Q4 FY2016 | Dec 31, 2016 | -$23.99M | – |
| Q3 FY2016 | Sep 30, 2016 | -$17.84M | – |
See a number that looks wrong?